Boston Harbor Angels
VC Fund
Boston, United States
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation, etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful. Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years. They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group. The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director). They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
- Total investments:
- 109
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Boston Harbor Angels invests in
Stages Boston Harbor Angels invests in
Countries Boston Harbor Angels invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 51 contacts → | |||
Round size
- Seed
- $100k–$2.9M
- Angel
- $500k–$1.6M
- Series A
- $662k–$6M
Investment Focus
Industry
- Health Care 33 (30%)
- Biotechnology 32 (29%)
- Medical Device 14 (13%)
- Medical 11 (10%)
- Manufacturing 10 (9%)
Stage
- Angel 58 (53%)
- Seed 19 (17%)
- Series A 10 (9%)
- Series B 6 (6%)
- Funding Round 5 (5%)
Country
- United States 82 (75%)
- Canada 3 (3%)
- India 1 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Douglass
Member
|
Member | Total investments: 0 | Find email | |
Boris Batchvarov
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Candida Brush
Member
|
Member | Total investments: 0 | Find email | |
|
Cindy Devall
Member
|
Member | Total investments: 0 | Find email | |
David J. Powsner
Member
|
Member | Total investments: 0 | Find email | |
| See all 51 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients. | $13M / Seed / Feb 17, 2026 | ||
| Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series B / Aug 18, 2023 | ||
| Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $5.2M / Series B / Jun 03, 2022 | ||
| Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts. | $7.3M / Series A / Aug 08, 2021 | ||
| Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series A / May 03, 2021 | ||
| S'More Date they provide daters with a totally interactive way to learn more about a person before evaluating them on appearance. | $2.1M / Seed / Jan 26, 2021 | ||
| Enrich Therapeutics is a biotechnology startup focused on the development of novel single-cell isolation platform along with the critical life science applications. | $320K / Seed / Jul 15, 2020 | ||
| Mobile-based operating system to manage construction & architectural projects. PowerplayOS is a mobile app ecosystem that simplifies site-to-office communication to manage construction & architectural projects. Simplifying communication like-Material requestsMaterial inwarding notesGoods receiving notesPlanned scheduleHighlights,issues, RFIs, RFAs and more | Seed / Jan 01, 2020 | ||
| Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $4M / Series A / Sep 26, 2019 | ||
| DetraPel is a cleantech Advanced Materials company specializing in synthesizing & manufacturing PFAS-Free Protective Coatings. | $1M / Seed / Sep 12, 2019 | ||
| See all 109 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boston Harbor Angels invest in?
Boston Harbor Angels invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Angel and Seed stage. Most of the 109 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Boston Harbor Angels invest in?
Boston Harbor Angels typically joins rounds of $100k–$2.9M at Seed, $500k–$1.6M at Angel and $662k–$6M at Series A. These are whole funding-round sizes, not Boston Harbor Angels's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Boston Harbor Angels took part in.
How do I contact Boston Harbor Angels?
Public channels for Boston Harbor Angels include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boston Harbor Angels?
The team at Boston Harbor Angels includes Andrew Douglass (Member), Boris Batchvarov (Managing Director) and Candida Brush (Member), among 51 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
